Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
•
Hospital Medicine
Do you prefer using unfractionated heparin or low molecular weight heparin in stable patients presenting with NSTE ACS awaiting primary PCI (assuming normal renal function)?
Related Questions
In light of recent trials evaluating NPO before cath (CHOW NOW, SCOFF, etc.) are centers still restricting oral intake pre-procedure?
What is your preferred P2Y12 inhibitor to use upstream of STEMI cases, if you decide to administer an agent before proceeding to the cath lab?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
What factors do you consider for patients on an individual basis when establishing a post-cardiac arrest MAP goal after ROSC is achieved, considering some may benefit from higher MAP goals for optimal cerebral perfusion?
What is your approach to VTE prophylaxis in hospitalized patients who are already on DAPT?
What techniques do you find most helpful to optimize image acquisition for cardiac POCUS in patients with poor acoustic windows?
When do you usually introduce conversations regarding tracheostomy placement in patients with refractory status epilepticus, or other conditions where one may anticipate delayed awakening?
What is your approach to checking preoperative cardiac biomarkers such as troponin and BNP?
How do you consider and approach transition to hospice in a patient with HFrEF who does not appear to tolerate GDMT?
